^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HBM1022

    i
    Associations

    News

    Trials
    Company:
    Harbour BioMed
    Drug class:
    CCR8 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over2years
    HBM1022: an afucosylated anti-CCR8 antibody, depletes specifically tumor infiltrating Tregs and inhibits tumor growth with excellent safety profile in preclinical studies (SITC 2022)
    HBM1022 exhibits a potent antitumor activity as monotherapy and in combination with anti-PD (L)1 antibodies. HBM1022 has favorable pharmacokinetic properties and an excellent safety profile in cynomolgus monkey, which suggests a potential good safety profile in human.
    Preclinical • IO biomarker
    |
    CCR8 (C-C Motif Chemokine Receptor 8)
    |
    HBM1022